Skip to content

Clinical study of Shugan Hewei granule in the treatment of refractory gastroesophageal reflux disease with qi stagnation and phlegm obstruction

Clinical study of Shugan Hewei granule in the treatment of refractory gastroesophageal reflux disease

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003657
Enrollment
Unknown
Registered
2020-08-24
Start date
2020-10-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastroesophageal reflux disease

Interventions

Sponsors

Yueyang Hospital of Integrated Traditioanl Chinese and Western Medicine,Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: A. It was in accordance with the diagnostic criteria of qi stagnation and phlegm resistance type of acid vomiting (gastroesophageal reflux disease). B. Before this study, patients with gastroesophageal reflux disease (GERD) were treated with standard dose PPI for four weeks or more. C. The age is 18-70 years old, with no gender limit.

Exclusion criteria

Exclusion criteria: A. Patients with one of the following diseases: peptic ulcer, history of gastroesophageal and duodenal surgery, Zhuo AI syndrome, primary esophageal motility disorders (such as achalasia, scleroderma, primary esophageal spasm), malignant lesions of upper gastrointestinal tract, coronary heart disease, diabetes, drug-induced esophagitis, and psychotic patients. B. Pregnant women and allergic constitution patients. C. The patient himself is the researcher directly involved in this clinical study.

Design outcomes

Primary

MeasureTime frame
Observation of clinical symptoms;electrocardiogram;Quality of life assessment;Electronic gastroscope;

Countries

China

Contacts

Public ContactFang Shengquan
fsq20032003@163.com+86 021-65161782

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026